Michigan Med University of Michigan .
Welcome,         Profile    Billing    Logout  
 2 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Talpaz, Moshe
NCT04877522 / 2021-000602-17: Asciminib Roll-over Study

Recruiting
4
347
Europe, Canada, Japan, US, RoW
Asciminib single agent, ABL001, Asciminib, Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Sprycel
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
08/30
08/30
AIM4CML, NCT04666259: Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

Active, not recruiting
3
115
US
ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
06/23
07/24
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Calendar Jan 2024 - Dec 2024: Approval for myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
NCT05320198: Study of DISC-0974 in Participants With Myelofibrosis and Anemia

Recruiting
1/2
56
US
DISC-0974
Disc Medicine, Inc
Myelofibrosis; Anemia, Anemia, Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
10/24
10/24
SANRECO, NCT05499013: Study to Assess SLN124 in Patients With Polycythemia Vera

Recruiting
1/2
65
Europe, US, RoW
SLN124, Placebo
Silence Therapeutics plc
Polycythemia Vera
12/24
06/25
McCullough, Nancy
NCT04877522 / 2021-000602-17: Asciminib Roll-over Study

Recruiting
4
347
Europe, Canada, Japan, US, RoW
Asciminib single agent, ABL001, Asciminib, Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Sprycel
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
08/30
08/30
PAVO, NCT02445222 / 2014-001673-14: CAR-T Long Term Follow Up (LTFU) Study

Recruiting
3
1400
Europe, Canada, Japan, US, RoW
Previously treated CAR-T patients
Novartis Pharmaceuticals, University of Pennsylvania
Long Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access Program
02/36
02/36
NCT04702425: VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Active, not recruiting
1
37
Europe, Japan, US, RoW
VOB560, S65487, MIK665, S64315
Novartis Pharmaceuticals
Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML), Multiple Myeloma (MM)
07/24
07/24
AURORA US, NCT03737695: Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer

Suspended
N/A
300
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Medical Chart Review, Chart Review
Mayo Clinic, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Breast Carcinoma, Peritoneal Effusion, Recurrent Breast Carcinoma
09/24
11/24

Download Options